Ignite Creation Date:
2024-05-05 @ 11:25 AM
Last Modification Date:
2024-10-26 @ 9:07 AM
Study NCT ID:
NCT00035178
Status:
COMPLETED
Last Update Posted:
2005-06-24
First Post:
2002-05-02
Brief Title:
PharmacokineticsPharmacodynamics of Argatroban Injection in End-Stage Renal Disease Patients Undergoing Hemodialysis
Sponsor:
Texas Biotechnology Corporation
Organization:
Encysive Pharmaceuticals
Study Overview
Official Title:
Pharmacokinetics and Pharmacodynamics of Argatroban Injection in End-Stage Renal Disease ESRD Patients Undergoing Hemodialysis
Status:
COMPLETED
Status Verified Date:
2003-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The primary goals of this investigation are to provide guidance on how to dose Argatroban in patients undergoing hemodialysis and to assess the safety and tolerability of Argatroban in hemodialysis patients The secondary goal of the study will be to assess the adequacy of anticoagulation during hemodialysis
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None